Center for Fatty Liver Disease, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai 200092, China.
Department of Gastroenterology & Hepatology, Singapore General Hospital, Singapore, Singapore.
Hepatobiliary Pancreat Dis Int. 2024 Jun;23(3):241-248. doi: 10.1016/j.hbpd.2023.08.004. Epub 2023 Aug 3.
Nonalcoholic fatty liver disease (NAFLD) is associated with impaired renal function, and both diseases often occur alongside other metabolic disorders. However, the prevalence and risk factors for impaired renal function in patients with NAFLD remain unclear. The objective of this study was to identify the prevalence and risk factors for renal impairment in NAFLD patients.
All adults aged 18-70 years with ultrasound-diagnosed NAFLD and transient elastography examination from eight Asian centers were enrolled in this prospective study. Liver fibrosis and cirrhosis were assessed by FibroScan-aspartate aminotransferase (FAST), Agile 3+ and Agile 4 scores. Impaired renal function and chronic kidney disease (CKD) were defined by an estimated glomerular filtration rate (eGFR) with value of < 90 mL/min/1.73 m and < 60 mL/min/1.73 m, respectively, as estimated by the CKD-Epidemiology Collaboration (CKD-EPI) equation.
Among 529 included NAFLD patients, the prevalence rates of impaired renal function and CKD were 37.4% and 4.9%, respectively. In multivariate analysis, a moderate-high risk of advanced liver fibrosis and cirrhosis according to Agile 3+ and Agile 4 scores were independent risk factors for CKD (P< 0.05). Furthermore, increased fasting plasma glucose (FPG) and blood pressure were significantly associated with impaired renal function after controlling for the other components of metabolic syndrome (P< 0.05). Compared with patients with normoglycemia, those with prediabetes [FPG ≥ 5.6 mmol/L or hemoglobin A1c (HbA1c) ≥ 5.7%] were more likely to have impaired renal function (P< 0.05).
Agile 3+ and Agile 4 are reliable for identifying NAFLD patients with high risk of CKD. Early glycemic control in the prediabetic stage might have a potential renoprotective role in these patients.
非酒精性脂肪性肝病(NAFLD)与肾功能受损有关,这两种疾病常与其他代谢紊乱并存。然而,NAFLD 患者肾功能受损的患病率和危险因素仍不清楚。本研究旨在确定 NAFLD 患者肾功能受损的患病率和危险因素。
本前瞻性研究纳入了来自亚洲 8 个中心的年龄在 18-70 岁之间、经超声诊断为 NAFLD 且接受过瞬时弹性成像检查的所有成年人。肝纤维化和肝硬化通过 FibroScan-天门冬氨酸转氨酶(FAST)、Agile 3+和 Agile 4 评分进行评估。肾功能受损和慢性肾脏病(CKD)通过 CKD-Epidemiology Collaboration(CKD-EPI)方程估算肾小球滤过率(eGFR)<90mL/min/1.73m 和<60mL/min/1.73m 来定义。
在 529 例纳入的 NAFLD 患者中,肾功能受损和 CKD 的患病率分别为 37.4%和 4.9%。多变量分析显示,Agile 3+和 Agile 4 评分提示中高度进展性肝纤维化和肝硬化是 CKD 的独立危险因素(P<0.05)。此外,在控制代谢综合征的其他成分后,空腹血糖(FPG)和血压升高与肾功能受损显著相关(P<0.05)。与血糖正常的患者相比,血糖异常患者[FPG≥5.6mmol/L 或糖化血红蛋白(HbA1c)≥5.7%]更易发生肾功能受损(P<0.05)。
Agile 3+和 Agile 4 可用于识别患有 CKD 风险较高的 NAFLD 患者。在糖尿病前期阶段进行早期血糖控制可能对这些患者具有潜在的肾脏保护作用。